Symbols / NVCT Stock $25.95 +6.00% Nuvectis Pharma, Inc.

Healthcare • Biotechnology • United States • NCM
NVCT (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Ron Bentsur M.B.A.
Exch · Country NCM · United States
Market Cap 688.34M
Enterprise Value 624.22M
Income -29.59M
Sales —
FCF (ttm) -9.17M
Book/sh 0.54
Cash/sh 0.95
Employees 12
Insider 10d —
IPO Feb 04, 2022
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -27.03
PEG —
P/S —
P/B 48.41
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio 2.25
Current Ratio 2.27
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -1.31
EPS next Y -0.96
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-04
Earnings (prior) 2026-05-05
ROA -63.61%
ROE -154.43%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 26.53M
Shs Float 15.27M
Insider Own 42.13%
Instit Own 18.23%
Short Float 10.14%
Short Ratio 13.28
Short Interest 1.58M
52W High 26.85
vs 52W High -3.35%
52W Low 5.55
vs 52W Low 367.57%
Beta -0.07
Impl. Vol. 2.56%
Rel Volume 3.28
Avg Volume 115.84K
Volume 380.07K
Target (mean) $29.20
Tgt Median $30.00
Tgt Low $20.00
Tgt High $39.00
# Analysts 5
Recom Strong_buy
Prev Close $24.48
Price $25.95
Change 6.00%
About

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$29.20
Mean price target
2. Current target
$25.95
Latest analyst target
3. DCF / Fair value
$-6.22
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$25.95
Low
$20.00
High
$39.00
Mean
$29.20

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-06-22 main HC Wainwright & Co. Buy → Buy $39
2026-06-12 main HC Wainwright & Co. Buy → Buy $13
2025-08-04 main HC Wainwright & Co. Buy → Buy $10
2025-04-30 reit HC Wainwright & Co. Buy → Buy $15
2025-04-02 init Maxim Group — → Buy $17
2025-03-17 init Laidlaw & Co. — → Buy $19
2025-02-25 main HC Wainwright & Co. Buy → Buy $11
2024-08-06 reit HC Wainwright & Co. Buy → Buy $21
2024-05-08 reit HC Wainwright & Co. Buy → Buy $21
2023-09-15 reit HC Wainwright & Co. Buy → Buy $21
2023-03-07 reit HC Wainwright & Co. — → Buy $21
2023-02-10 reit HC Wainwright & Co. — → Buy $21
2022-07-13 init Ladenburg Thalmann — → Buy $21
2022-05-10 main HC Wainwright & Co. — → Buy $21
2022-03-02 init HC Wainwright & Co. — → Buy $14
News
RSS: Latest NVCT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-06-11 OLIVIERO JAMES F III Director — 35,000 $0.00 $0
2026-06-11 HOBERMAN KENNETH Director — 35,000 $0.00 $0
2026-06-11 KAPLAN MATTHEW L. Director — 35,000 $0.00 $0
2026-06-11 SANCHEZ JUAN Director — 35,000 $0.00 $0
2026-01-06 BENTSUR RON Chief Executive Officer — 150,000 $0.00 $0
2026-01-06 SHEMESH SHAY Officer — 150,000 $0.00 $0
2026-01-06 PORADOSU ENRIQUE Officer — 150,000 $0.00 $0
2026-01-06 CARSON MICHAEL J. Officer — 61,200 $0.00 $0
2025-11-05 BENTSUR RON Chief Executive Officer — 5,000 $5.72 $28,600
2025-11-05 KAPLAN MATTHEW L. Director — 11,000 $5.84 $64,240
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
27.57
+38.93%
19.85
-13.32%
22.90
+19.04%
19.23
Research And Development
18.15
+40.52%
12.92
-16.01%
15.38
+16.28%
13.23
Selling General And Administration
9.42
+35.96%
6.93
-7.82%
7.52
+25.14%
6.01
General And Administrative Expense
9.42
+35.96%
6.93
-7.82%
7.52
+25.14%
6.01
Salaries And Wages
2.42
+15.78%
2.09
-9.01%
2.30
+30.87%
1.76
Other Gand A
6.40
+51.25%
4.23
-3.31%
4.38
+42.67%
3.07
Total Expenses
27.57
+38.93%
19.85
-13.32%
22.90
+19.04%
19.23
Operating Income
-27.57
-38.93%
-19.85
+13.32%
-22.90
-19.04%
-19.23
Total Operating Income As Reported
-27.57
-38.93%
-19.85
+13.32%
-22.90
-19.04%
-19.23
EBITDA
-27.57
-38.93%
-19.85
+13.32%
-22.90
-19.04%
-19.23
Normalized EBITDA
-27.57
-38.93%
-19.85
+13.32%
-22.90
-19.04%
-19.23
EBIT
-27.57
-38.93%
-19.85
+13.32%
-22.90
-19.04%
-19.23
Net Income
-26.44
-39.17%
-19.00
+14.65%
-22.26
-16.64%
-19.09
Pretax Income
-26.44
-39.17%
-19.00
+14.65%
-22.26
-16.64%
-19.09
Net Non Operating Interest Income Expense
1.13
+33.65%
0.85
+32.97%
0.64
+327.52%
0.15
Net Interest Income
1.13
+33.65%
0.85
+32.97%
0.64
+327.52%
0.15
Interest Income Non Operating
1.13
+33.65%
0.85
+32.97%
0.64
+327.52%
0.15
Interest Income
1.13
+33.65%
0.85
+32.97%
0.64
+327.52%
0.15
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-26.44
-39.17%
-19.00
+14.65%
-22.26
-16.64%
-19.09
Net Income From Continuing Operation Net Minority Interest
-26.44
-39.17%
-19.00
+14.65%
-22.26
-16.64%
-19.09
Net Income From Continuing And Discontinued Operation
-26.44
-39.17%
-19.00
+14.65%
-22.26
-16.64%
-19.09
Net Income Continuous Operations
-26.44
-39.17%
-19.00
+14.65%
-22.26
-16.64%
-19.09
Normalized Income
-26.44
-39.17%
-19.00
+14.65%
-22.26
-16.64%
-19.09
Net Income Common Stockholders
-28.87
-51.95%
-19.00
+14.65%
-22.26
-16.64%
-19.09
Otherunder Preferred Stock Dividend
2.43
0.00
—
—
Diluted EPS
-1.32
-18.92%
-1.11
+22.38%
-1.43
+5.30%
-1.51
Basic EPS
-1.32
-18.92%
-1.11
+22.38%
-1.43
+5.30%
-1.51
Basic Average Shares
21.81
+27.46%
17.11
+10.01%
15.56
+22.90%
12.66
Diluted Average Shares
21.81
+27.46%
17.11
+10.01%
15.56
+22.90%
12.66
Diluted NI Availto Com Stockholders
-28.87
-51.95%
-19.00
+14.65%
-22.26
-16.64%
-19.09
Insurance And Claims
0.60
-1.16%
0.61
-28.03%
0.84
-28.83%
1.18
Line Item Trend 2023-12-31
Total Assets
19.18
Current Assets
19.18
Cash Cash Equivalents And Short Term Investments
19.13
Cash And Cash Equivalents
19.13
Other Current Assets
0.06
Total Non Current Assets
0.00
Non Current Deferred Assets
—
Total Liabilities Net Minority Interest
6.98
Current Liabilities
6.98
Payables And Accrued Expenses
3.19
Payables
2.77
Accounts Payable
2.77
Other Payable
—
Current Accrued Expenses
0.41
Pensionand Other Post Retirement Benefit Plans Current
3.80
Total Non Current Liabilities Net Minority Interest
0.00
Preferred Securities Outside Stock Equity
—
Stockholders Equity
12.20
Common Stock Equity
12.20
Capital Stock
0.00
Common Stock
0.00
Share Issued
17.42
Ordinary Shares Number
17.42
Treasury Shares Number
0.00
Additional Paid In Capital
66.45
Retained Earnings
-54.24
Total Equity Gross Minority Interest
12.20
Total Capitalization
12.20
Working Capital
12.20
Invested Capital
12.20
Net Tangible Assets
12.20
Tangible Book Value
12.20
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-16.01
-30.72%
-12.25
+23.24%
-15.95
-17.66%
-13.56
Cash Flow From Continuing Operating Activities
-16.01
-30.72%
-12.25
+23.24%
-15.95
-17.66%
-13.56
Net Income From Continuing Operations
-26.44
-39.17%
-19.00
+14.65%
-22.26
-16.64%
-19.09
Stock Based Compensation
6.03
+24.17%
4.86
+3.25%
4.71
+175.63%
1.71
Change In Working Capital
4.40
+132.24%
1.90
+18.36%
1.60
-58.08%
3.82
Change In Payables And Accrued Expense
3.05
+1907.24%
0.15
-87.82%
1.25
-69.86%
4.14
Change In Accrued Expense
-0.72
-270.59%
0.42
-69.36%
1.39
-39.41%
2.29
Change In Payable
3.78
+1483.15%
-0.27
-96.40%
-0.14
-107.51%
1.85
Change In Account Payable
3.78
+1483.15%
-0.27
-96.40%
-0.14
-107.51%
1.85
Change In Other Working Capital
1.35
-23.15%
1.76
+24.06%
1.42
-27.37%
1.95
Change In Other Current Assets
-0.00
+93.33%
-0.01
-104.25%
0.35
+209.97%
-0.32
Investing Cash Flow
0.00
0.00
0.00
0.00
Financing Cash Flow
29.11
+149.79%
11.65
-22.75%
15.09
-45.75%
27.81
Cash Flow From Continuing Financing Activities
29.11
+149.79%
11.65
-22.75%
15.09
-45.75%
27.81
Net Common Stock Issuance
31.21
+159.31%
12.04
+127.57%
5.29
-83.41%
31.88
Proceeds From Stock Option Exercised
—
0.00
-100.00%
11.19
0.00
Net Other Financing Charges
-2.10
-449.74%
-0.38
+72.60%
-1.39
+65.74%
-4.07
Changes In Cash
13.10
+2309.27%
-0.59
+31.60%
-0.87
-106.08%
14.25
Beginning Cash Position
18.53
-3.10%
19.13
-4.34%
19.99
+248.19%
5.74
End Cash Position
31.63
+70.69%
18.53
-3.10%
19.13
-4.34%
19.99
Free Cash Flow
-16.01
-30.72%
-12.25
+23.24%
-15.95
-17.66%
-13.56
Interest Paid Supplemental Data
—
—
—
—
Income Tax Paid Supplemental Data
—
—
—
—
Common Stock Issuance
31.21
+159.31%
12.04
+127.57%
5.29
-83.41%
31.88
Issuance Of Capital Stock
31.21
+159.31%
12.04
+127.57%
5.29
-83.41%
31.88
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category